Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK
Corcept Therapeutics rallied for a second day on Wednesday, soaring 19.66 percent to finish at $40.47 apiece, as investors snapped up shares after securing the green light of the Food and Drug Administration...







